藥物交互作用
Liposomal doxorubicin + Trastuzumab
嚴重程度: 嚴重
Liposomal doxorubicin and Trastuzumab: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Trastuzumab can cause cardiomyopathy and left ventricular dysfunction, and the risk is markedly higher when it follows or is combined with anthracyclines. Liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, but additive cardiac injury remains a concern.
用白話說明這項交互作用的意義
Liposomal doxorubicin and Trastuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Liposomal doxorubicin belongs to Oncology; Trastuzumab belongs to Oncology.
為什麼會發生
Additive cardiotoxicity: anthracycline myocyte injury combined with HER2 pathway inhibition impairing cardiomyocyte repair.
處置方式
Assess LVEF before and periodically during therapy, and avoid concurrent use outside carefully monitored settings. Hold trastuzumab or stop the anthracycline if LVEF falls significantly or heart failure symptoms appear.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Liposomal doxorubicin 的其他交互作用
Trastuzumab 的其他交互作用
常見問題
Can I take Liposomal doxorubicin with Trastuzumab?
MediHelp rates the interaction as major. Liposomal doxorubicin and Trastuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Trastuzumab can cause cardiomyopathy and left ventricular dysfunction, and the risk is markedly higher when it follows or is combined with anthracyclines. Liposomal doxorubicin is less cardiotoxic than conventional doxorubicin, but additive cardiac injury remains a concern.
How serious is the interaction between Liposomal doxorubicin and Trastuzumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Assess LVEF before and periodically during therapy, and avoid concurrent use outside carefully monitored settings. Hold trastuzumab or stop the anthracycline if LVEF falls significantly or heart failure symptoms appear.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
